

Codes ATC: J01DD01

Indication	Inflammatory and other diseases of prostate	Code ICD11: GA91.Z
INN	Cefotaxime	
Type de médicament	Chemical agent	
Groupes d'antibiotiques	 WATCH	
Type de liste	Liste de base	
Additional notes	3rd generation cephalosporin of choice for use in hospitalized neonates.	
Formulations	Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt)	
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2023 (TRS 1049)	
Sexe	Mâle	
Âge	Adolescents et adultes	
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique	
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite <a href="#">sur les brevets</a> . 	
Wikipédia	Cefotaxime 	
DrugBank	Cefotaxime 	

### Recommandation du comité d'experts

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc.

### Recommandations de la LME : Inflammatory and other diseases of prostate

**Premier choix****Second choix**

## MILD TO MODERATE

ciprofloxacin

cefotaxime

ceftriaxone

## SEVERE

cefotaxime

co-prescrite avec [amikacin](#)

ceftriaxone

co-prescrite avec [amikacin](#)

